Gene · 6154
RPL26: ribosomal protein L26
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPL26: ribosomal protein L26. Genes, record 6154. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6154
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P61254 | Large ribosomal subunit protein uL24 | 145 | 180 | Ensembl, GeneID, HGNC |
Source UniProt
Patents40
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62016 | P61254 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 17437 | P61254 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 8816 | P61254 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 17437 | P61254 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 8816 | P61254 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74032 | P61254 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74034 | P61254 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74037 | P61254 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74038 | P61254 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 177003 | P61254 | Espacenet |
1 to 10 of 40
See all 40 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants840
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPL26 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 6 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA033572 | Cancer Center Support Grant | 5 | 2025 |
| ZICBC011079 | Molecular Diagnostics Core Laboratory | 5 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 4 | 2025 |
| P30CA014236 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 840Source NIH's project files
See all 840 nih grantsPapers1,580
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CDK5RAP3-Mediated Mitochondrial RQC Alleviates Pathological Cardiac Hypertrophy. | Circ Res | 2026 | 42565227 | PubTator, text mining | PubMed |
| A Practical Experimental Protocol for Identification and Validation of UFMylation Substrate in Human Cells. | Bio Protoc | 2026 | 42516571 | PubTator, text mining | PubMed |
| A 3D RNA-protein proximity ligation protocol detecting the heterogeneity of LISRR-RPL26 interactions in patient-derived melanoma tumor explants. | STAR Protoc | 2026 | 42485184 | PubTator, text mining | PubMed |
| The UFSP2-ODR4 complex spatially confines and dynamically controls UFM1 deconjugation to safeguard neuronal proteostasis. | Mol Cell | 2026 | 42425078 | PubTator, text mining | PubMed |
| Fasting disrupts the InsP₆-HDAC3 axis to drive ER stress-mediated clearance of DNA-damaged cells and enforce tissue quality control. | bioRxiv | 2026 | 42244775 | PubTator, text mining | PubMed |
| A severe neurodevelopmental syndrome linked to a South Asian founder variant in the UFMylation adaptor CDK5RAP3. | Acta Neuropathol | 2026 | 42045457 | PubTator, text mining | PubMed |
| Successful Treatment of Tumor-Induced Lactic Acidosis With Tris-Hydroxymethyl Aminomethane (THAM). | Kidney Med | 2026 | 41890786 | PubTator, text mining | PubMed |
| The coordinated action of UFMylation and the RQC pathways clears arrested polypeptides at the ER. | EMBO J | 2026 | 41882226 | PubTator, text mining | PubMed |
| Mitochondrial dysfunction and programmed cell death in Alzheimer's disease: A retrospective bioinformatics study. | Medicine (Baltimore) | 2026 | 41861196 | PubTator, text mining | PubMed |
| Single-cell transcriptomics reveals heterogeneity and immune microenvironment in lymphatic metastasis of head and neck squamous cell carcinoma. | Genes Immun | 2026 | 41839993 | PubTator, text mining | PubMed |
1 to 10 of 1,580
See all 1,580 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6154
GET https://conductscience.org/api/genes/v1/6154/patents?page=2